Hypersensitivity reactions in a mouse model prompted the agency to suspend Denali’s planned Phase I development for DNL952 ...
At least $65 million slated for 14 of 35 Alzheimer's disease research centers is in limbo, with funding expected to run out on April 30. (The Guardian) In a surprise finding, the silent X chromosome ...
Denali’s ALS drug DNL343 failed to show efficacy in slowing disease progression. Analyst lowers Denali’s fair value estimate from $32 to $30 per share. PPI and Industrial Production drop Wednesday ...
Denali Therapeutics Inc.'s DNL343 failed to meet the primary endpoint in the phase 2/3 HEALY ALS trial, but potential biomarker analyses in 2025 may offer a path forward. Despite the trial setback in ...
Please provide your email address to receive an email when new articles are posted on . Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its ...
In studies by Massachusetts General Hospital, an AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...
Stock futures were mixed on Tuesday as investors looked ahead to the release of the Job Openings and Labor Turnover Survey (JOLTS) later in the day. Denali Therapeutics (NASDAQ:DNLI) shares plunged 7% ...
On Monday, Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating DNL343 for amyotrophic lateral sclerosis.
After Denali Therapeutics (DNLI) reported DNL343 did not meet the primary or key secondary endpoints in the Phase 2/3 HEALEY trial in amyotrophic lateral sclerosis at 24 weeks, Jefferies says “this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results